The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

By sjmartinez • December 2, 2024

Secord AA, Lewin SN, Murphy CG, Cecere SC, Barquín A, Gálvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Pérez MJR, Bonaventura A, Diver EJ, Ayuk SA, Wang Y, Corr BR, Salutari V. The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial. Ann Oncol. 2024 Nov 29:S0923-7534(24)04948-2. doi: 10.1016/j.annonc.2024.11.011. Epub ahead of print. PMID: 39617145.

Tags: antibody-drug conjugate, Folate receptor alpha, heavily pretreated (max 6), Infectious Diseases, Mirvetuximab soravtansine, Platinum-sensitive ovarian cancer, Publications

The Use of Genetics and Immunology in the Diagnosis and Care of Advanced Coccidioidomycosis: Where Are We Going?

Thiagarajan K, Mishra S, Purdie R, Torres B, Johnson RH, Butte MJ. The Use of Genetics and Immunology in the Diagnosis and Care of Advanced[...]

Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2

Grinspoon SK, Zhao S, Martinez E, Fichtenbaum CJ, Chu SM, Diggs MR, Umbleja T, McCallum S, Fitch KV, Triant VA, Currier JS, Aberg JA, Malvestutto[...]

Preferences for HIV prevention conditional cash transfers among Black/African American and Latinx cisgender MSM in Los Angeles

Moucheraud C, Trujillo D, Wagner Z, Garland W, Smith T, Hoffman RM, Landovitz RJ. Preferences for HIV prevention conditional cash transfers among Black/African American and[...]